Table 1B.
Baseline biomarker status
| CSF analysis | FDG-PET | Amyloid-PET | DAT-SPECT | EEG | Biomarker status1 | Additional neuropsychology | |
| SCD (n = 134) | 21 (15.7%) | 47 (35.1%) | 1 (0.7%) | 1 (0.7%) | 68 (50.7%) | 116 (86.6%) | 133 (99.2%) |
| MCI (n = 102) | 25 (24.5%) | 46 (45.1%) | 1 (0.9%) | 1 (0.9%) | 46 (45.1%) | 92 (90.2%) | 98 (96.1%) |
| Dementia (n = 212) | 68 (32.1%) | 106 (50%) | 6 (2.8%) | 4 (1.9%) | 84 (39.6%) | 194 (91.5%) | 197 (92.9%) |
| Total (n = 448) | 114 (25.4%) | 199 (44.4%) | 8 (1.8%) | 6 (1.3%) | 198 (44.2%) | 402 (87.9%) | 428 (95.5%) |
Biomarkers available at baseline evaluation. Table stratified by syndrome diagnosis as diagnosed by the consensus conference. CSF analysis including beta-amyloid1–42, total-tau and phospho-tau. All included patients had an available MRI at baseline as part of inclusion criteria. 1 Biomarker status indicating at least one additional biomarker (CSF, FDG-PET, amyloid-PET, DAT-SPECT, EEG), besides MRI, available at baseline.